Tyra Biosciences, Inc. - Common Stock (TYRA)
24.35
-1.08 (-4.25%)
NASDAQ· Last Trade: Sep 16th, 6:32 PM EDT
Detailed Quote
| Previous Close | 25.43 |
|---|---|
| Open | 25.58 |
| Bid | 22.16 |
| Ask | 27.00 |
| Day's Range | 24.15 - 26.15 |
| 52 Week Range | 11.82 - 40.65 |
| Volume | 1,138,496 |
| Market Cap | 1.05B |
| PE Ratio (TTM) | -12.18 |
| EPS (TTM) | -2.0 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 1,038,192 |
Chart
About Tyra Biosciences, Inc. - Common Stock (TYRA)
Tyra Biosciences is a biotechnology company focused on developing innovative therapies for patients with genetically defined cancers. By harnessing advanced protein modulation technologies, the company aims to create targeted treatments that address specific genetic drivers of cancer, improving the efficacy and safety of therapies for individuals with unmet medical needs. Through its commitment to precision medicine, Tyra seeks to transform the landscape of cancer care by advancing drug candidates through clinical development and fostering collaborations within the scientific community. Read More
News & Press Releases
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. (“Tyra” or the “Company”) (NASDAQ: TYRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · September 15, 2026
Gapping stocks in Wednesday's sessionchartmill.com
Via Chartmill · September 9, 2026
Top movers in Wednesday's pre-market sessionchartmill.com
Via Chartmill · September 9, 2026
Which stocks are experiencing notable movement on Friday?chartmill.com
Via Chartmill · September 4, 2026
Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary technology to advance its drug pipeline.
Via The Motley Fool · May 17, 2026

This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms.
Via The Motley Fool · March 20, 2026

Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships.
Via The Motley Fool · March 19, 2026

Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing a diversified clinical pipeline.
Via The Motley Fool · March 19, 2026

Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.
Via The Motley Fool · March 18, 2026

This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and rare epilepsies.
Via The Motley Fool · March 18, 2026

Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs.
Via The Motley Fool · February 23, 2026

Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.
Via The Motley Fool · February 23, 2026

Spyre Therapeutics develops preclinical monoclonal antibody therapies targeting inflammatory bowel disease and related conditions.
Via The Motley Fool · February 23, 2026

Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in biopharma.
Via The Motley Fool · February 23, 2026

Nuvalent develops targeted cancer therapies, advancing clinical candidates for patients with limited treatment options in oncology.
Via The Motley Fool · February 23, 2026
Focused on precision oncology and rare genetic diseases, this biotech reported a significant insider sale amid strong one-year stock gains.
Via The Motley Fool · December 23, 2025
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via Chartmill · April 22, 2025
Via Benzinga · April 22, 2025
Via Benzinga · April 22, 2025
Via Benzinga · April 22, 2025
Via Benzinga · April 14, 2025
Via Benzinga · April 3, 2025